These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 31786688)

  • 1. Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma.
    Petrova E; Zielinski V; Bolm L; Schreiber C; Knief J; Thorns C; Bronsert P; Timme-Bronsert S; Bausch D; Perner S; Keck T; Wellner U
    Virchows Arch; 2020 Apr; 476(4):561-568. PubMed ID: 31786688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system.
    Karamitopoulou E; Wartenberg M; Zlobec I; Cibin S; Worni M; Gloor B; Lugli A
    Histopathology; 2018 Jul; 73(1):137-146. PubMed ID: 29495092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.
    O'Connor K; Li-Chang HH; Kalloger SE; Peixoto RD; Webber DL; Owen DA; Driman DK; Kirsch R; Serra S; Scudamore CH; Renouf DJ; Schaeffer DF
    Am J Surg Pathol; 2015 Apr; 39(4):472-8. PubMed ID: 25634751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and prognostic significance of tumor budding in pancreatic ductal adenocarcinomas.
    Argon A; Öz Ö; Kebat TA
    Indian J Pathol Microbiol; 2023; 66(1):38-43. PubMed ID: 36656208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma.
    Kohler I; Bronsert P; Timme S; Werner M; Brabletz T; Hopt UT; Schilling O; Bausch D; Keck T; Wellner UF
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():78-84. PubMed ID: 25827809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
    Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A
    Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: From histology to clinical implications.
    Lee SJ; Sung YN; Kim SJ; Shin S; Cho H; Hruban RH; Hong SM
    Pancreatology; 2020 Oct; 20(7):1486-1494. PubMed ID: 32948429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor budding is a prognostic factor linked to epithelial mesenchymal transition in pancreatic ductal adenocarcinoma. Study report and literature review.
    Chouat E; Zehani A; Chelly I; Njima M; Maghrebi H; Bani MA; Njim L; Zakhama A; Haouet S; Kchir N
    Pancreatology; 2018 Jan; 18(1):79-84. PubMed ID: 29233500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Cell Division Cycle Associated 2 Expression on Pancreatic Ductal Adenocarcinoma.
    Wang MY; Niu ZY; Gao XG; Zhou L; Liao Q; Zhao YP
    Chin Med Sci J; 2016 Sep; 31(3):149-154. PubMed ID: 27733221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma.
    Lohneis P; Sinn M; Klein F; Bischoff S; Striefler JK; Wislocka L; Sinn BV; Pelzer U; Oettle H; Riess H; Denkert C; Bläker H; Jühling A
    Br J Cancer; 2018 May; 118(11):1485-1491. PubMed ID: 29755112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma.
    Dal Molin M; Brant A; Blackford AL; Griffin JF; Shindo K; Barkley T; Rezaee N; Hruban RH; Wolfgang CL; Goggins M
    PLoS One; 2016; 11(10):e0164195. PubMed ID: 27732623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
    Robinson SM; Rahman A; Haugk B; French JJ; Manas DM; Jaques BC; Charnley RM; White SA
    Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor budding is an independent prognostic marker in early stage oral squamous cell carcinoma: With special reference to the mode of invasion and worst pattern of invasion.
    Shimizu S; Miyazaki A; Sonoda T; Koike K; Ogi K; Kobayashi JI; Kaneko T; Igarashi T; Ueda M; Dehari H; Miyakawa A; Hasegawa T; Hiratsuka H
    PLoS One; 2018; 13(4):e0195451. PubMed ID: 29672550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
    PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors in Resected Pancreatic Ductal Adenocarcinoma: Is Neutrophil-Lymphocyte Ratio a Useful Marker?
    Merlo I; Ardiles V; Sanchez-Clariá R; Fratantoni E; de Santibañes E; Pekolj J; Mazza O; de Santibañes M
    J Gastrointest Cancer; 2023 Jun; 54(2):580-588. PubMed ID: 35653056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
    Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
    Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
    Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion?
    Buc E; Couvelard A; Kwiatkowski F; Dokmak S; Ruszniewski P; Hammel P; Belghiti J; Sauvanet A
    Eur J Surg Oncol; 2014 Nov; 40(11):1578-85. PubMed ID: 24923739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Surgical therapy of pancreatic cancer - 5 years survival].
    Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
    Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.